Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, 17176 Stockholm, Sweden.
Acta Derm Venereol. 2019 Apr 1;99(4):375-378. doi: 10.2340/00015555-3121.
Dupilumab, the first biologic approved for treatment of atopic dermatitis, has demonstrated significant clinical effect and quality of life-enhancing capacity in clinical trials. In these, dupilumab-associated conjunctivitis where reported in a minority of patients. The present case series describe 10 patients treated with dupilumab where eye complications were very common. We have described patient characteristics, including FLG mutations, atopic history and clinical effect of dupilumab. Nine of 10 developed eye-complications, most commonly conjunctivitis (in 7/10). Other adverse events were herpes simplex virus uveitis and varicella-zoster virus meningitis. Although our case series is small, we conclude that dupilumab is an effective treatment option in severe atopic dermatitis, but that the risk of adverse events from the eyes and recurrence of herpes virus infections should be kept in mind. Close collaboration with an ophthalmologist is recommended, especially among patients with severe, long-lasting atopic dermatitis and/or previous eye disease.
度普利尤单抗是首个获批用于治疗特应性皮炎的生物制剂，在临床试验中显示出显著的临床疗效和改善生活质量的能力。在这些临床试验中，少数患者报告了度普利尤单抗相关的结膜炎。本病例系列描述了 10 名接受度普利尤单抗治疗的患者，他们的眼部并发症非常常见。我们描述了患者的特征，包括 FLG 突变、特应性病史和度普利尤单抗的临床疗效。10 名患者中有 9 名出现眼部并发症，最常见的是结膜炎（7/10）。其他不良事件包括单纯疱疹病毒葡萄膜炎和水痘-带状疱疹病毒脑膜炎。尽管我们的病例系列很小，但我们的结论是，度普利尤单抗是严重特应性皮炎的有效治疗选择，但应注意眼部不良事件和疱疹病毒感染复发的风险。建议与眼科医生密切合作，特别是在严重、持久的特应性皮炎和/或既往眼部疾病患者中。
